Search research articles
Contact Us
Filters
Showing results (11-20 of 60) with videos related to
Page
of 6
Sort By:
Harefuah
|
April 23, 2005
[Opsoclonus myoclonus with ataxia]
Ilan Asher, Daniel Elbirt, M Kushnir, et al.
Clinics in Dermatology
|
June 15, 2010
The management of systemic lupus erythematosus: Facts and controversies
Daniel Elbirt, Dalia Sthoeger, Ilan Asher, et al.
The Israel Medical Association Journal : IMAJ
|
September 18, 2012
Novel biological treatments for systemic lupus erythematosus: current and future modalities
Shira Bezalel, Ilan Asher, Daniel Elbirt, et al.
The Israel Medical Association Journal : IMAJ
|
November 13, 2024
Allergic Rhinitis in Israel: A Multicenter Study of Allergic Rhinitis Across Three Climate Zones
Rachel Eisenberg, Allon Raphael, Matan Risling, et al.
Clinical Immunology (Orlando, Fla.)
|
September 1, 2018
Indoleamine-2,3-dioxygenase in murine and human systemic lupus erythematosus: Down-regulation by the tolerogeneic peptide hCDR1
Zev Sthoeger, Amir Sharabi, Heidy Zinger, et al.
The Israel Medical Association Journal : IMAJ
|
December 1, 2012
Immunoglobulin G4 and related diseases
Zev Sthoeger, Ilan Asher, Shira Rosenberg-Bezalel, et al.
Plos One
|
April 5, 2013
The tolerogenic peptide, hCDR1, down-regulates the expression of interferon-α in murine and human systemic lupus erythematosus
Zev Sthoeger, Heidy Zinger, Amir Sharabi, et al.
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology
|
June 27, 2022
Early childhood allergy linked with development of attention deficit hyperactivity disorder and autism spectrum disorder
Shay Nemet, Ilan Asher, Israel Yoles, et al.
Immunology
|
February 5, 2009
High alpha-defensin levels in patients with systemic lupus erythematosus
Zev M Sthoeger, Shira Bezalel, Nava Chapnik, et al.
The Israel Medical Association Journal : IMAJ
|
July 24, 2007
The beneficial effects of Xolair (omalizumab) as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available treatment (GINA 2002 step IV)--the Israeli arm of the INNOVATE study
Zev M Sthoeger, Abraham Eliraz, Ilan Asher, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 60) with videos related to
Sort By:
Page
of 6
Harefuah
|
April 23, 2005
[Opsoclonus myoclonus with ataxia]
Ilan Asher, Daniel Elbirt, M Kushnir, et al.
Clinics in Dermatology
|
June 15, 2010
The management of systemic lupus erythematosus: Facts and controversies
Daniel Elbirt, Dalia Sthoeger, Ilan Asher, et al.
The Israel Medical Association Journal : IMAJ
|
September 18, 2012
Novel biological treatments for systemic lupus erythematosus: current and future modalities
Shira Bezalel, Ilan Asher, Daniel Elbirt, et al.
The Israel Medical Association Journal : IMAJ
|
November 13, 2024
Allergic Rhinitis in Israel: A Multicenter Study of Allergic Rhinitis Across Three Climate Zones
Rachel Eisenberg, Allon Raphael, Matan Risling, et al.
Clinical Immunology (Orlando, Fla.)
|
September 1, 2018
Indoleamine-2,3-dioxygenase in murine and human systemic lupus erythematosus: Down-regulation by the tolerogeneic peptide hCDR1
Zev Sthoeger, Amir Sharabi, Heidy Zinger, et al.
The Israel Medical Association Journal : IMAJ
|
December 1, 2012
Immunoglobulin G4 and related diseases
Zev Sthoeger, Ilan Asher, Shira Rosenberg-Bezalel, et al.
Plos One
|
April 5, 2013
The tolerogenic peptide, hCDR1, down-regulates the expression of interferon-α in murine and human systemic lupus erythematosus
Zev Sthoeger, Heidy Zinger, Amir Sharabi, et al.
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology
|
June 27, 2022
Early childhood allergy linked with development of attention deficit hyperactivity disorder and autism spectrum disorder
Shay Nemet, Ilan Asher, Israel Yoles, et al.
Immunology
|
February 5, 2009
High alpha-defensin levels in patients with systemic lupus erythematosus
Zev M Sthoeger, Shira Bezalel, Nava Chapnik, et al.
The Israel Medical Association Journal : IMAJ
|
July 24, 2007
The beneficial effects of Xolair (omalizumab) as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available treatment (GINA 2002 step IV)--the Israeli arm of the INNOVATE study
Zev M Sthoeger, Abraham Eliraz, Ilan Asher, et al.
Page
of 6